Comparison of Clinical Profiles of All Patients Who Did and Did Not Experience MACE
| Characteristic | MACE (n = 12 [55%]) | No MACE (n = 10 [45%]) | P |
| Age (y) | 70 ± 10 | 71 ± 14 | 0.950 |
| Male | 9 (75%) | 7 (70%) | 1.000 |
| NYHA class | 0/0/1/11 | 0/2/1/7 | 0.185 |
| BNP (pg/mL) | 664 (420–794) | 408 (184–687) | 0.277 |
| Hypertension | 12 (100%) | 9 (90%) | 0.455 |
| Dyslipidemia | 9 (75%) | 6 (60%) | 0.652 |
| Diabetes mellitus | 7 (58%) | 6 (60%) | 1.000 |
| Previous myocardial infarction | 12 (100%) | 8 (80%) | 0.195 |
| SSS | 25 (21–28) | 20 (15–25) | 0.209 |
| SRS | 27 (23–29) | 22 (15–29) | 0.427 |
| Low MBR-IR | 10 (83%) | 1 (10%) | 0.002 |
| Rest LVEF (%) | 31(30–39) | 38 (31–53) | 0.477 |
| Treatments after myocardial perfusion imaging | |||
| PCI | 3 (25%) | 1 (10%) | 0.594 |
| CABG | 1 (8%) | 1 (10%) | 1.000 |
| Nicorandil | 7 (58%) | 5 (50%) | 1.000 |
| ARB | 11 (92%) | 6 (60%) | 0.135 |
| β-blocker | 10 (83%) | 9 (90%) | 1.000 |
| Statin | 10 (83%) | 6 (60%) | 0.348 |
| Pacemaker implantation | 2 (17%) | 0 (0%) | 0.481 |
| ICD implantation | 1 (8%) | 0 (0%) | 1.000 |
NYHA = New York Heart Association; BNP = brain natriuretic peptide; SSS = summed stress score; SRS = summed rest score; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; ARB = angiotensin receptor blocker; ICD = implantable cardioverter-defibrillator.
Categorical data are expressed as counts (%), and continuous data are expressed as mean ± SD or median (25th–75th).